Antibody monitoring technology using mass spectrometry contributed to a determination of clinical outcomes for the treatment of rheumatoid arthritis by Kyoto University Hospital and Shimadzu Corporation November 4, 2021November 4, 2021 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Mass spectrometry technology contributed to a…Mass spectrometry technology contributed to the…Shimadzu Receives First Award for Fragrance Oil and…Contributing to CO2 Reduction and…Promoting Development and Commercialization of…Promoting Development and Commercialization of…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
